Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Prostate Cancer

Free Subscription Articles published in Eur Urol Retrieve available abstracts of 229 articles: HTML format Text format

Single Articles

March 2010
1. STENMAN UH
   Words of wisdom. Re: Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness.
   Eur Urol. 2010;57:541-2.
   PubMed     Text format     Related articles   
   
   
   
2. VAN DEN BERGH RC
   Words of wisdom. Re: Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.
   Eur Urol. 2010;57:540-1.
   PubMed     Text format     Related articles   
   
   
   
3. HERR HW
   Words of wisdom. Re: Rethinking screening for breast cancer and prostate cancer.
   Eur Urol. 2010;57:540.
   PubMed     Text format     Related articles   
   
   
   
4. CLARKE NW , Marberger M
   Open to debate. The motion: GnRH antagonists are the new way forward in hormonal therapy.
   Eur Urol. 2010;57:534-7.
   PubMed     Text format     Related articles   
   
   
   
5. RABBANI F , Yunis LH, Pinochet R, Nogueira L, et al
   Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy.
   Eur Urol. 2010;57:371-86.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. LOPEZ JI
   Re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in radical prostatectomy with no residual carcinoma and with a previous positive biopsy conveys a wrong message to clinicians and patients: why is cancer not present in the ra
   Eur Urol. 2010;57:e21.
   PubMed     Text format     Related articles   
   
   
   February 2010
7. BRANDT A , Bermejo JL, Sundquist J, Hemminki K, et al
   Age-Specific Risk of Incident Prostate Cancer and Risk of Death from Prostate Cancer Defined by the Number of Affected Family Members.
   Eur Urol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. JANSEN FH , van Schaik RH, Kurstjens J, Horninger W, et al
   Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection.
   Eur Urol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. TROTTIER G , Fleshner NE
   Words of wisdom. Re: XMRV is present in malignant prostate epithelium and is associated with prostate cancer, especially high-grade tumors.
   Eur Urol. 2010;57:358.
   PubMed     Text format     Related articles   
   
   
   
10. BEUZEBOC P
    Words of wisdom. Re: anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
    Eur Urol. 2010;57:356-7.
    PubMed     Text format     Related articles   
    
    
    January 2010
11. JENTZMIK F , Stephan C, Miller K, Schrader M, et al
    Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours.
    Eur Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. ENGEL J , Bastian PJ, Baur H, Beer V, et al
    Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer.
    Eur Urol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2009
13. BRIGANTI A , Passoni N, Ferrari M, Capitanio U, et al
    When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2009
14. TOMBAL B
    Prostate Cancer, Depression, and Risk of Suicide: Should We Pay More Attention?
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
15. TOMBAL B , Miller K, Boccon-Gibod L, Schroder F, et al
    Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. BOLENZ C , Gupta A, Hotze T, Ho R, et al
    Cost Comparison of Robotic, Laparoscopic, and Open Radical Prostatectomy for Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. GRAEFEN M
    Editorial Comment on: Cost Comparison of Robotic, Laparoscopic and Open Radical Prostatectomy for Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
18. FRIEDMAN AE
    Re: Kim N. Chi, Anders Bjartell, David Dearnaley et al. Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. Eur Urol 2009;56:594-605.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
19. BILL-AXELSON A , Garmo H, Lambe M, Bratt O, et al
    Suicide Risk in Men with Prostate-Specific Antigen-Detected Early Prostate Cancer: A Nationwide Population-Based Cohort Study from PCBaSe Sweden.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. CHI KN
    Reply to A. Edward Friedman's Letter to the Editor re: Kim N. Chi, Anders Bjartell, David Dearnaley, et al. Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. Eur Urol 2009;56:594-605.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
21. DREWA T
    Re: Minja J. Pfeiffer, Jack A. Schalken. Stem Cell Characteristics in Prostate Cancer Cell Lines. Eur Urol. In press. doi:10.1016/j.eururo.2009.01.015.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
22. PFEIFFER MJ , Schalken JA
    Reply to Tomasz Drewa's Letter to the Editor re: Minja J. Pfeiffer, Jack A. Schalken. Stem Cell Characteristics in Prostate Cancer Cell Lines. Eur Urol. In press. doi:10.1016/j.eururo.2009.01.015.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    October 2009
23. EFSTATHIOU E , Abrahams NA, Tibbs RF, Wang X, et al
    Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. CHUN FK , de la Taille A, van Poppel H, Marberger M, et al
    Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659-68.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
25. MOROTE J
    Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659-668.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
26. SCHMID HP , Engeler DS
    Re: Selective Inhibition of CYP17 with Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer.
    Eur Urol. 2009;56:744-5.
    PubMed     Text format     Related articles   
    
    
    
27. ITO K
    Re: mortality results from a randomized prostate-cancer screening trial.
    Eur Urol. 2009;56:743-4.
    PubMed     Text format     Related articles   
    
    
    September 2009
28. ALCOVER J , Filella X
    Re: Alberto Briganti, Michael L. Blute, James H. Eastham, et al. Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol 2009;55:1251-65.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
29. SCATTONI V
    Reply from Authors re: Michael W. Kattan, J. Stephen Jones. The Ultimate Prostate Cancer Biopsy Decision Support Tool. Eur Urol. In press. doi:10.1016/j.eururo.2009.08.015.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
30. ROOBOL MJ , Steyerberg EW, Kranse R, Wolters T, et al
    A Risk-Based Strategy Improves Prostate-Specific Antigen-Driven Detection of Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. MESSING E
    Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al.
    Eur Urol. 2009;56:572.
    PubMed     Text format     Related articles   
    
    
    
32. VAN DER POEL HG
    Words of wisdom. Re: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Tran C, Ouk S, Clegg NJ, et al.
    Eur Urol. 2009;56:575.
    PubMed     Text format     Related articles   
    
    
    
33. SELLI C
    Words of wisdom. Re: Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current decision strategies. Lecouvet FE, Geukens D, Sta
    Eur Urol. 2009;56:573.
    PubMed     Text format     Related articles   
    
    
    
34. GODOY G , Chade DC, Shariat SF
    Words of wisdom. Re: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V.
    Eur Urol. 2009;56:573-5.
    PubMed     Text format     Related articles   
    
    
    August 2009
35. KATTAN MW , Jones JS
    The Ultimate Prostate Cancer Biopsy Decision Support Tool.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
36. BOORMANS JL , Hermans KG, Made AC, van Leenders GJ, et al
    Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERG Does Not Predict Response to Endocrine Treatment in Hormone-Naive, Node-Positive Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. VICKERS AJ
    Reply from Authors re: Riccardo Bartoletti. Prostate-Specific Antigen Dynamics and Prostate Cancer Diagnosis. Eur Urol. In press. doi:10.1016/j.eururo.2009.07.048.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
38. PLOUSSARD G , Xylinas E, Salomon L, Allory Y, et al
    The Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. ABRAHAMSSON PA
    Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. VICKERS AJ , Wolters T, Savage CJ, Cronin AM, et al
    Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. BARTOLETTI R
    Prostate-Specific Antigen Dynamics and Prostate Cancer Diagnosis.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
42. SOLSONA E
    Re: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastasis and improves survival: long-term follow-up of a randomized clinical trial.
    Eur Urol. 2009;56:398-9.
    PubMed     Text format     Related articles   
    
    
    
43. KLIMENT J
    Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.
    Eur Urol. 2009;56:397.
    PubMed     Text format     Related articles   
    
    
    
44. BOLENZ C , Pelzer AE
    Re: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
    Eur Urol. 2009;56:396.
    PubMed     Text format     Related articles   
    
    
    July 2009
45. WOLTERS T , Roobol MJ, van Leeuwen PJ, van den Bergh RC, et al
    Should Pathologists Routinely Report Prostate Tumour Volume? The Prognostic Value of Tumour Volume in Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. ROOBOL MJ , Kerkhof M, Schroder FH, Cuzick J, et al
    Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. BELLMUNT J , Rosenberg JE, Choueiri TK
    Recent Progress and Pitfalls in Testing Novel Agents in Castration-Resistant Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
48. ISBARN H
    Reply to A. Edward Friedman's Letter to the Editor re: Hendrik Isbarn, Jehonathan H. Pinthus, Leonard S. Marks, et al. Testosterone and Prostate Cancer: Revisiting Old Paradigms. Eur Urol 2009;56:48-56.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
49. GASSER T
    Re: surveillance and deferred treatment for localized prostate cancer. Population based study in the national prostate cancer register of sweden.
    Eur Urol. 2009;56:219.
    PubMed     Text format     Related articles   
    
    
    
50. VOGELZANG NJ
    Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71.
    Eur Urol. 2009;56:220.
    PubMed     Text format     Related articles   
    
    
    June 2009
51. CHI KN , Bjartell A, Dearnaley D, Saad F, et al
    Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. JOCHAM D , Doehn C
    Words of wisdom. Re: the efficacy and safety of degarelix: a 12-month, comparative, randomized, open- label, parallel-group phase III study in patients with prostate cancer.
    Eur Urol. 2009;55:1488-9.
    PubMed     Text format     Related articles   
    
    
    
53. ROOBOL MJ
    Words of wisdom. Re: Mortality results from a randomized prostate- cancer screening Trial.
    Eur Urol. 2009;55:1481-2.
    PubMed     Text format     Related articles   
    
    
    May 2009
54. YOSSEPOWITCH O
    Editorial Comment on: Adjuvant High-Dose Intensity-Modulated Radiotherapy after Radical Prostatectomy for Prostate Cancer: Clinical Results in 104 Patients.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
55. DA POZZO LF
    Editorial Comment on: Adjuvant High-Dose Intensity-Modulated Radiotherapy after Radical Prostatectomy for Prostate Cancer: Clinical Results in 104 Patients.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
56. OST P , Fonteyne V, Villeirs G, Lumen N, et al
    Adjuvant High-Dose Intensity-Modulated Radiotherapy after Radical Prostatectomy for Prostate Cancer: Clinical Results in 104 Patients.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. ABRAHAMSSON PA , Artibani W, Chapple CR, Wirth M, et al
    European Association of Urology Position Statement on Screening for Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
58. BEDOGNETTI D , Rubagotti A, Conti G, Francesca F, et al
    An Open, Randomised, Multicentre, Phase 3 Trial Comparing the Efficacy of Two Tamoxifen Schedules in Preventing Gynaecomastia Induced by Bicalutamide Monotherapy in Prostate Cancer Patients.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. VERHAGEN PC
    Words of wisdom. Re: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
    Eur Urol. 2009;55:1239-40.
    PubMed     Text format     Related articles   
    
    
    
60. ZIETMAN A
    Words of wisdom. Re: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
    Eur Urol. 2009;55:1240.
    PubMed     Text format     Related articles   
    
    
    April 2009
61. TOMLINS SA , Bjartell A, Chinnaiyan AM, Jenster G, et al
    ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
62. GARDINER RA , Sweeney C, Tilley WD
    Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
63. HOLMBERG L
    Prostate Cancer Screening: The Need For Problem-Solving that Puts Men's Interests First.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
64. PINKAWA M , Gontero P
    The Motion: Radiotherapy for Prostate Cancer Preserves Sexual Function to a Greater Extent Than Nerve Sparing Radical Prostatectomy.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
65. ISBARN H , Pinthus JH, Marks LS, Montorsi F, et al
    Testosterone and Prostate Cancer: Revisiting Old Paradigms.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. BRATT O
    Re: Jean-Louis Campos-Fernandes, Laurence Bastien, Nathalie Nicolaiew, et al. Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy. Eur Urol 2009;55:600-9.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
67. PLOUSSARD G , de la Taille A
    Reply to Ola Bratt's Letter to the Editor re: Jean-Louis Campos-Fernandes, Laurence Bastien, Nathalie Nicolaiew, et al. Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy. Eur Urol 2009;55:600-9.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
68. MORRIS MJ , Huang D, Kelly WK, Slovin SF, et al
    Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
69. MORGENTALER A , Traish AM
    Reply to A. Edward Friedman's Letter to the Editor re: Abraham Morgentaler, Abdulmaged M. Traish. Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth. Eur Urol 2009;55:310-21.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
70. MOUL JW
    Will the Global Economic Downturn Affect Prostate Cancer Care? Pelvic Lymphadenectomy as an Example.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
71. VAN DER POEL HG
    Chemical Castration and Survival in Low-risk Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
72. FRIEDMAN AE
    Re: Abraham Morgentaler, Abdulmaged M. Traish. Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth. Eur Urol 2009;55:310-21.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
73. WONG YN , Freedland SJ, Egleston B, Vapiwala N, et al
    The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
74. BEUZEBOC P
    Words of wisdom. Re: Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
    Eur Urol. 2009;55:992.
    PubMed     Text format     Related articles   
    
    
    
75. ALBERTSEN P
    Words of wisdom. Re: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial.
    Eur Urol. 2009;55:989-90.
    PubMed     Text format     Related articles   
    
    
    March 2009
76. BRIGANTI A
    Editorial Comment on: Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
77. CHUN FK , de la Taille A, van Poppel H, Marberger M, et al
    Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
78. MOUL JW , Tang P, Sun L
    Editorial Comment on: Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
79. TILLING K , Garmo H, Metcalfe C, Holmberg L, et al
    Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
80. WARD JF
    Editorial Comment on: Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-Century Radiotherapy.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
81. HEIDENREICH A , Richter S, Thuer D, Pfister D, et al
    Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-Century Radiotherapy.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
82. PATEL A
    Editorial Comment on: Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-Century Radiotherapy.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
83. GALLINA A
    Editorial Comment on: Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
84. YOSSEPOWITCH O
    Editorial Comment on: Tumor Grade, Treatment, and Relative Survival in a Population-Based Cohort of Men with Potentially Curable Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
85. LADJEVARDI S , Sandblom G, Berglund A, Varenhorst E, et al
    Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
86. BRIGANTI A , Blute ML, Eastham JH, Graefen M, et al
    Pelvic Lymph Node Dissection in Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
87. AUS G
    Editorial Comment on: Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
88. ALBERTSON PC
    Editorial Comment on: Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
89. BASTIAN PJ , Carter BH, Bjartell A, Seitz M, et al
    Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
90. MARKS LS
    Words of wisdom. Re: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.
    Eur Urol. 2009;55:750-1.
    PubMed     Text format     Related articles   
    
    
    February 2009
91. JURHILL RR , van der Veen H, van Leenders GJ, Verhagen PC, et al
    Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
92. VAN DER POEL HG
    Editorial Comment on: A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
93. SZMULEWITZ R , Mohile S, Posadas E, Kunnavakkam R, et al
    A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
94. MORGIA G , De Renzis C
    CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
95. VAN POPPEL H
    Is Radiotherapy Useful in Node-Positive Prostate Cancer Patients after Radical Prostatectomy?
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
96. CALAIS DA SILVA FE , Bono AV, Whelan P, Brausi M, et al
    Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
97. DA POZZO LF , Cozzarini C, Briganti A, Suardi N, et al
    Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
98. RITTMASTER RS , Fleshner NE, Thompson IM
    Pharmacological Approaches to Reducing the Risk of Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
99. ORVIETO M , Eggener S
    Editorial Comment on: Pharmacological Approaches to Reducing the Risk of Prostate Cancer.
    Eur Urol. 2009.
    PubMed     Text format     Related articles   
    
    
    
100. ADOLFSSON J
     Editorial Comment on: Pharmacological Approaches to Reducing the Risk of Prostate Cancer.
     Eur Urol. 2009.
     PubMed     Text format     Related articles   
     
     
     
101. SALONIA A
     Words of wisdom. Re: Quality of life and satisfaction with outcome among prostate-cancer survivors.
     Eur Urol. 2009;55:526-7.
     PubMed     Text format     Related articles   
     
     
     
102. LANGE PH
     Words of wisdom. Re: Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard?
     Eur Urol. 2009;55:524-5.
     PubMed     Text format     Related articles   
     
     
     
103. LOEB S , Carter HB
     Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representat
     Eur Urol. 2009;55:523-4.
     PubMed     Text format     Related articles   
     
     
     
104. SCHELLHAMMER PF
     Words of wisdom. Re: Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
     Eur Urol. 2009;55:522-3.
     PubMed     Text format     Related articles   
     
     
     
105. EGEVAD L
     Editorial comment on: Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series.
     Eur Urol. 2009;55:403.
     PubMed     Text format     Related articles   
     
     
     
106. LOPEZ-BELTRAN A , Montironi R, Cheng L
     Editorial comment on: Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series.
     Eur Urol. 2009;55:402.
     PubMed     Text format     Related articles   
     
     
     
107. VAN DER KWAST TH
     Editorial comment on: Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series.
     Eur Urol. 2009;55:401.
     PubMed     Text format     Related articles   
     
     
     
108. ISBARN H , Ahyai SA, Chun FK, Budaus L, et al
     Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series.
     Eur Urol. 2009;55:394-401.
     PubMed     Text format     Related articles    Abstract available
     
     
     
109. GRAEFEN M
     Editorial comment on: Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
     Eur Urol. 2009;55:410-1.
     PubMed     Text format     Related articles   
     
     
     
110. PAPAREL P , Cronin AM, Savage C, Scardino PT, et al
     Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
     Eur Urol. 2009;55:404-10.
     PubMed     Text format     Related articles    Abstract available
     
     
     January 2009
111. SEITZ M , Shukla-Dave A, Bjartell A, Touijer K, et al
     Functional Magnetic Resonance Imaging in Prostate Cancer.
     Eur Urol. 2009.
     PubMed     Text format     Related articles    Abstract available
     
     
     
112. WENNEMUTH G
     Editorial Comment on: Stem Cell Characteristics in Prostate Cancer Cell Lines.
     Eur Urol. 2009.
     PubMed     Text format     Related articles   
     
     
     
113. HARKONEN P
     Editorial Comment on: Stem Cell Characteristics in Prostate Cancer Cell Lines.
     Eur Urol. 2009.
     PubMed     Text format     Related articles   
     
     
     
114. PFEIFFER MJ , Schalken JA
     Stem Cell Characteristics in Prostate Cancer Cell Lines.
     Eur Urol. 2009.
     PubMed     Text format     Related articles    Abstract available
     
     
     
115. THOENY HC , Triantafyllou M, Birkhaeuser FD, Froehlich JM, et al
     Combined Ultrasmall Superparamagnetic Particles of Iron Oxide-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging Reliably Detect Pelvic Lymph Node Metastases in Normal-Sized Nodes of Bladder and Prostate Cancer Patients.
     Eur Urol. 2009.
     PubMed     Text format     Related articles    Abstract available
     
     
     
116. EISENBERGER MA
     Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Bar
     Eur Urol. 2009;55:248.
     PubMed     Text format     Related articles   
     
     
     
117. EASTHAM JA
     Words of wisdom. Re: Prostate cancer-specific survival following salvage radiotherapy versus observation in men with biochemical recurrence after radical prostatectomy. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. JAMA
     Eur Urol. 2009;55:247.
     PubMed     Text format     Related articles   
     
     
     
118. RUUTU M , Rannikko A
     Words of wisdom. Re: Active surveillance for the management of prostate cancer in a contemporary cohort. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Cancer 2008;112:2664-70.
     Eur Urol. 2009;55:244-5.
     PubMed     Text format     Related articles   
     
     
     December 2008
119. FICARRA V , Novara G, Galfano A
     Precursor Isoform of Prostate-Specific Antigen and Human Kallikrein 2: Two New Promising Biomarkers for the Unsolved Challenge of Early Prostate Cancer Detection.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
120. FEICKE A , Baumgartner M, Talimi S, Schmid DM, et al
     Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer: Surgical Technique and Experience with the First 99 Cases.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
121. MOTTRIE A
     Editorial Comment on: Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer: Surgical Technique and Experience with the First 99 Cases.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
122. TOUIJER K
     Editorial Comment on: Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer: Surgical Technique and Experience with the First 99 Cases.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
123. BRIGANTI A
     Oestrogens and Prostate Cancer: Novel Concepts about an Old Issue.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
124. SAUVAIN JL
     Editorial Comment on: A Study of Diffusion-Weighted Magnetic Resonance Imaging in Men with Untreated Localized Prostate Cancer on Active Surveillance.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
125. VAN AS NJ , de Souza NM, Riches SF, Morgan VA, et al
     A Study of Diffusion-Weighted Magnetic Resonance Imaging in Men with Untreated Localised Prostate Cancer on Active Surveillance.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
126. BRIGANTI A , Karakiewicz PI, Joniau S, Van Poppel H, et al
     The Motion: Nomograms Should Become a Routine Tool in Determining Prostate Cancer Prognosis.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
127. VAN POPPEL H
     Words of wisdom. Re: long-term outcome following three-dimensional conformal/intensity-modulated external- beam radiotherapy for clinical stage T3 prostate cancer.
     Eur Urol. 2008;54:1440-1.
     PubMed     Text format     Related articles   
     
     
     
128. SCHALKEN JA
     Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.
     Eur Urol. 2008;54:1438-9.
     PubMed     Text format     Related articles   
     
     
     November 2008
129. KVALE R , Hernes E, Bray F
     Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests? Eur Urol 2008;54:262-73.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
130. CRAWFORD ED , Abrahamsson PA
     Reply to Rune Kvale, Eivor Hernes and Freddie Bray's Letter to the Editor re: E. David Crawford, Per-Anders Abrahamsson. PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests? Eur Urol 2008;54:262-73.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
131. JANSEN FH , Roobol M, Jenster G, Schroder FH, et al
     Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
132. JAMES ND , Caty A, Borre M, Zonnenberg BA, et al
     Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
133. HAKENBERG OW
     Editorial Comment on: Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
134. WALZ J , Chun FK, Klein EA, Reuther A, et al
     Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
135. BASTIAN PJ
     Editorial Comment on: Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
136. NOVARA G
     Editorial Comment on: Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
137. AHYAI SA , Schlom T
     Editorial Comment on: Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
138. ALCARAZ A , Hammerer P, Tubaro A, Schroder FH, et al
     Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
139. BRIGANTI A
     Platinum Priority - Rebuttal from Author re: George N. Thalmann. Positive Lymph Nodes at Lymphadenectomy for Prostate Cancer: Where Do We Set the Tiller? Eur Urol. In press. doi:10.1016/j.eururo.2008.10.039.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
140. THALMANN GN
     Positive Lymph Nodes at Lymphadenectomy for Prostate Cancer: Where Do We Set the Tiller?
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
141. BONKHOFF H , Berges R
     The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
142. TOMBAL B
     Words of wisdom. Re: toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
     Eur Urol. 2008;54:1202-3.
     PubMed     Text format     Related articles   
     
     
     
143. DANESHMAND S
     Words of wisdom. Re: use of androgen deprivation therapy for metastatic prostate cancer in older men.
     Eur Urol. 2008;54:1201-2.
     PubMed     Text format     Related articles   
     
     
     
144. JUNG K
     Words of wisdom. Re: the metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.
     Eur Urol. 2008;54:1198-9.
     PubMed     Text format     Related articles   
     
     
     
145. HAESE A , de la Taille A, van Poppel H, Marberger M, et al
     Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
     Eur Urol. 2008;54:1081-8.
     PubMed     Text format     Related articles    Abstract available
     
     
     October 2008
146. DREWA T
     Re: Fritz H. Schroder, Karl-Heinz Kurth, Sophie D. Fossa et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatmen
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
147. SEITZ M , Gratzke C
     Editorial Comment on: Combined Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging in the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
148. UMBEHR M , Bachmann LM, Held U, Kessler TM, et al
     Combined Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging in the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
149. BERRUTI A , Ortega C, Fusco V
     Re: Christan Walter, Bilal Al-Nawas, Knut A. Grotz, et al. Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. Eur Urol 2008;54:1066-72.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
150. ISBARN H , Boccon-Gibod L, Carroll PR, Montorsi F, et al
     Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
151. ITALIANO A , Fizazi K
     Rebuttal from Authors re: Joaquim Bellmunt. Chemotherapy for Prostate Cancer in Senior Adults: Are We Treating the Elderly or the Frail? Eur Urol. In press. doi:10.1016/j.eururo.2008.08.065.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
152. VAN DEN BERGH RC , Roemeling S, Roobol MJ, Aus G, et al
     Reply from Authors re: Peter C. Albertsen. The Treatment Paradigm Shifts Again on Prostate Cancer. Eur Urol. In press. doi: 10.1016/j.eururo.2008.09.014.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
153. VERGUNST H , Langenhuijsen JF
     Rebuttal from Authors re: J. Stephen Jones. Ten Misconceptions Regarding Cryotherapy for Prostate Cancer. Eur Urol. In press. doi:10.1016/j.eururo.2008.08.064.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
154. BRIGANTI A , Karnes JR, Da Pozzo LF, Cozzarini C, et al
     Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatectomy,
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
155. BANGMA CH
     Words of wisdom. Re: Prostate cancer stem cells: a new target for therapy. Maitland NJ, Collins AT.
     Eur Urol. 2008;54:944-5.
     PubMed     Text format     Related articles   
     
     
     
156. VILLIERS A
     Words of wisdom. Re: Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Collin SM, Martin RM, Metcalfe C, et al.
     Eur Urol. 2008;54:942-3.
     PubMed     Text format     Related articles   
     
     
     
157. SCATTONI V
     Words of wisdom. Re: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European randomized study of screening for prostate cancer (Rotterdam). Wolters T, Roobol MJ, Bangma CH, Schroder PH.
     Eur Urol. 2008;54:945-6.
     PubMed     Text format     Related articles   
     
     
     
158. TAN GY , Tewari AK
     Words of wisdom. Re: Cumulative association of five genetic variants with prostate cancer. Zheng SL, Sun J, Wiklund F, et al.
     Eur Urol. 2008;54:943-4.
     PubMed     Text format     Related articles   
     
     
     
159. CAPITANIO U , Briganti A, Shariat SF, Karakiewicz PI, et al
     The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective.
     Eur Urol. 2008;54:717-9.
     PubMed     Text format     Related articles   
     
     
     
160. MENON M , Bhandari M
     Unhappy patients: musings of two surgical nihilists.
     Eur Urol. 2008;54:723-5.
     PubMed     Text format     Related articles   
     
     
     
161. EASTHAM JA
     Robotic-assisted prostatectomy: is there truth in advertising?
     Eur Urol. 2008;54:720-2.
     PubMed     Text format     Related articles   
     
     
     
162. HARNDEN P , Shelley MD, Naylor B, Coles B, et al
     Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review.
     Eur Urol. 2008;54:728-39.
     PubMed     Text format     Related articles    Abstract available
     
     
     
163. NIEDER AM , Soloway MS
     It's not a radical prostatectomy, it's a total prostatectomy.
     Eur Urol. 2008;54:715-6.
     PubMed     Text format     Related articles   
     
     
     September 2008
164. ALBERTSEN PC
     The Treatment Paradigm Shifts Again on Prostate Cancer.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
165. SCIARRA A
     Editorial Comment on: Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
166. TOMBAL B
     Editorial Comment on: Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
167. MORGENTALER A , Traish AM
     Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
168. VAN DEN BERGH RC , Roemeling S, Roobol MJ, Aus G, et al
     Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
169. SCHRODER FH , Kurth KH, Fossa SD, Hoekstra W, et al
     Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Random
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
170. VALDAGNI R , Scardino PT, Denis L, Kattan MW, et al
     Predictive Modeling in Prostate Cancer: A Conference Summary.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
171. GANSWINDT U , Belka C
     Reply to Chris Parker and Matthew R. Sydes' Letter to the Editor re: Ute Ganswindt, Arnulf Stenzl, Michael Bamberg and Claus Belka Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer-A New Standard? Eur Urol 2008;54:528-42.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
172. RAGAVAN N , Singh PB, Martin FL, Baird AD, et al
     Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891). Eur Urol 2008;53:941-9.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
173. PARKER C , Sydes MR
     Re: Ute Ganswindt, Arnulf Stenzl, Michael Bamberg And Claus Belka. Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer-A New Standard? Eur Urol 2008;54:528-42.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
174. JOHANSSON E , Bill-Axelson A, Holmberg L, Onelov E, et al
     Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
175. DAVIS JW , Chang DW, Chevray P, Wang R, et al
     Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy with versus without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Cancer.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
176. KORFAGE IJ
     Editorial Comment on: Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
177. GONTERO P
     Editorial Comment on: Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy with versus without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Canc
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
178. GATTELLARI M , Ward JE
     Editorial Comment on: Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
179. EDEN CG
     Editorial Comment on: Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy with versus without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Canc
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
180. BELLMUNT J
     Chemotherapy for Prostate Cancer in Senior Adults: Are We Treating the Elderly or the Frail?
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
181. JONES JS
     Ten Misconceptions Regarding Cryotherapy for Prostate Cancer.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
182. LANGENHUIJSEN JF , Broers EM, Vergunst H
     Cryosurgery for Prostate Cancer: an Update on Clinical Results of Modern Cryotechnology.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
183. SCATTONI V
     Re: saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation.
     Eur Urol. 2008;54:688-90.
     PubMed     Text format     Related articles   
     
     
     
184. MIZUTANIAB K , Pienta KJ
     Re: RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastasis model.
     Eur Urol. 2008;54:688.
     PubMed     Text format     Related articles   
     
     
     
185. COLEMAN JA
     Editorial comment on: MR-guided biopsy of the prostate: an overview of techniques and a systematic review.
     Eur Urol. 2008;54:525-6.
     PubMed     Text format     Related articles   
     
     
     
186. PONDMAN KM , Futterer JJ, ten Haken B, Schultze Kool LJ, et al
     MR-guided biopsy of the prostate: an overview of techniques and a systematic review.
     Eur Urol. 2008;54:517-27.
     PubMed     Text format     Related articles    Abstract available
     
     
     
187. SCIARRA A
     Editorial comment on: MR-guided biopsy of the prostate: an overview of techniques and a systematic review.
     Eur Urol. 2008;54:526-7.
     PubMed     Text format     Related articles   
     
     
     
188. GIANNANTONI A , Mearini E, Zucchi A, Costantini E, et al
     Bladder and urethral sphincter function after radical retropubic prostatectomy: a prospective long-term study.
     Eur Urol. 2008;54:657-64.
     PubMed     Text format     Related articles    Abstract available
     
     
     
189. GOLIJANIN D , Palapattu GS
     Editorial comment on: bladder and urethral sphincter function after radical retropubic prostatectomy: a prospective long-term study.
     Eur Urol. 2008;54:664.
     PubMed     Text format     Related articles   
     
     
     August 2008
190. STUDER UE , Collette L
     Reply to Magdi Mounir Kirollos' Letter to the Editor re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 M0 Prostate Cancer Not Suitable for Local Curative Treatment (EOR
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
191. WALTER C , Al-Nawas B, Grotz KA, Thomas C, et al
     Reply to Athanassios Kyrgidis, Zisis Teleioudis and Konstantinos Vahtsevanos' Letter to the Editor re: Christian Walter, Bilal Al-Nawas, Knut A. Grotz, et al. Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate C
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
192. KIROLLOS MM
     Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anders
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
193. KYRGIDIS A , Teleioudis Z, Vahtsevanos K
     Re: Christian Walter, Bilal Al-Nawas, Knut A. Grotz, et al. Prevalence and Risk Factors of Bisphosphonate Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. Eur Urol. In press. doi:10.1016/j.eu
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
194. MARTORANA G , Schiavina R, Franceschelli A
     Should We Perform Imaging-Guided Lymph Node Dissection in Patients with Lymphatic Recurrence of Prostate Cancer after Radical Prostatectomy?
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
195. BRIGANTI A
     Reply to Tommaso Cai, Riccardo Bartoletti and Gabriella Nesi's Letter to the Editor re: Alberto Briganti, Umberto Capatanio, Felix K.-H. Chun et al. Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatecto
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
196. CAI T , Nesi G, Bartoletti R
     Re: Alberto Briganti, Umberto Capatanio, Felix K.-H. Chun, et al. Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Canc
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
197. ROSENTHAL MA
     Editorial Comment on: Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
198. ITALIANO A , Ortholan C, Oudard S, Pouessel D, et al
     Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer.
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
199. CLARKE NW
     Bisphosphonates in Hormone-Refractory Prostate Cancer: Do We Have a Toxicity Problem?
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
200. LOEB S , Kettermann A, Ferrucci L, Landis P, et al
     Rebuttal from Authors re: Axel Heidenreich. Identification of High-Risk Prostate Cancer: Role of Prostate-Specific Antigen, PSA Doubling Time and PSA Velocity. Eur Urol. In press. doi:10.1016/j.eururo.2008.06.077.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
201. JOVO B , Vuk S
     Re: Alberto Briganti, Umberto Capitanio, Felix K.-H. Chun et al. Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cance
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
202. COLLETTE L
     Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
     Eur Urol. 2008;54:462.
     PubMed     Text format     Related articles   
     
     
     
203. GLEAVE M
     Re: Cumulative association of five genetic variants with prostate cancer.
     Eur Urol. 2008;54:460-1.
     PubMed     Text format     Related articles   
     
     
     July 2008
204. BRANDI G , de Rosa F, Danesi R, Montini GC, et al
     Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?
     Eur Urol. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     
     
205. LOEB S
     Does PCA3 Help Identify Clinically Significant Prostate Cancer?
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
206. HEIDENREICH A
     Identification of High-Risk Prostate Cancer: Role of Prostate-Specific Antigen, PSA Doubling Time, and PSA velocity.
     Eur Urol. 2008.
     PubMed     Text format     Related articles   
     
     
     
207. MAFFEZZINI M
     Editorial comment on: long-term rates of undetectable psa with initial observation and delayed salvage radiotherapy after radical prostatectomy.
     Eur Urol. 2008;54:95-6.
     PubMed     Text format     Related articles   
     
     
     
208. LOEB S , Roehl KA, Viprakasit DP, Catalona WJ, et al
     Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy.
     Eur Urol. 2008;54:88-94.
     PubMed     Text format     Related articles    Abstract available
     
     
     
209. EGGENER SE , Guillonneau B
     Laparoscopic radical prostatectomy: ten years later, time for evidence-based foundation.
     Eur Urol. 2008;54:4-7.
     PubMed     Text format     Related articles   
     
     
     
210. SHARIAT SF , Margulis V, Karakiewicz PI
     Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? Eur Urol 2008;54:11-12.
     Eur Urol. 2008;54:13-5.
     PubMed     Text format     Related articles   
     
     
     
211. CATTO JW
     More nomograms or better evidence of efficacy: what do we need in urologic oncology?
     Eur Urol. 2008;54:11-2.
     PubMed     Text format     Related articles   
     
     
     
212. DE KORTE FI , van Werkum JW, Vijverberg PL, Ten Berg JM, et al
     Late coronary stent thrombosis complicating urologic surgery.
     Eur Urol. 2008;54:221-5.
     PubMed     Text format     Related articles    Abstract available
     
     
     June 2008
213. FINNEY RUTTEN LJ
     Editorial comment on: decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
     Eur Urol. 2008;53:1193.
     PubMed     Text format     Related articles   
     
     
     
214. AVERY KN , Blazeby JM, Lane JA, Neal DE, et al
     Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
     Eur Urol. 2008;53:1186-93.
     PubMed     Text format     Related articles    Abstract available
     
     
     
215. SUARDI N , Scattoni V, Briganti A, Salonia A, et al
     Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement.
     Eur Urol. 2008;53:1180-5.
     PubMed     Text format     Related articles    Abstract available
     
     
     May 2008
216. ARTIBANI W , Novara G
     Cancer-related outcome and learning curve in retropubic radical prostatectomy: "if you need an operation, the most important step is to choose the right surgeon".
     Eur Urol. 2008;53:874-6.
     PubMed     Text format     Related articles   
     
     
     
217. SCHRODER FH , Bangma CH, Roobol MJ
     Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
     Eur Urol. 2008;53:901-8.
     PubMed     Text format     Related articles    Abstract available
     
     
     
218. ANDERSON J
     Androgen-deprivation therapy-it's all a matter of timing.
     Eur Urol. 2008;53:869-71.
     PubMed     Text format     Related articles   
     
     
     
219. HEIDENREICH A
     Radical prostatectomy in 2007: oncologic control and preservation of functional integrity.
     Eur Urol. 2008;53:877-9.
     PubMed     Text format     Related articles   
     
     
     
220. VICKERS AJ , Bianco FJ, Gonen M, Cronin AM, et al
     Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.
     Eur Urol. 2008;53:960-6.
     PubMed     Text format     Related articles    Abstract available
     
     
     
221. STOLZENBURG JU , Rabenalt R, Do M, Schwalenberg T, et al
     Intrafascial nerve-sparing endoscopic extraperitoneal radical prostatectomy.
     Eur Urol. 2008;53:931-40.
     PubMed     Text format     Related articles    Abstract available
     
     
     
222. ASHLEY RA , Inman BA, Routh JC, Mynderse LA, et al
     Reassessing the diagnostic yield of saturation biopsy of the prostate.
     Eur Urol. 2008;53:976-81.
     PubMed     Text format     Related articles    Abstract available
     
     
     
223. PATEL A
     Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
     Eur Urol. 2008;53:982-3.
     PubMed     Text format     Related articles   
     
     
     
224. PHILIP J
     Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
     Eur Urol. 2008;53:981-2.
     PubMed     Text format     Related articles   
     
     
     
225. HORENBLAS S
     Editorial comment on: diabetes mellitus: does it impair urinary continence after radical cystoprostatectomy and ileal orthotopic bladder substitution?
     Eur Urol. 2008;53:1046-7.
     PubMed     Text format     Related articles   
     
     
     
226. KESSLER TM , Ochsner K, Studer UE, Thalmann GN, et al
     Diabetes mellitus: does it impair urinary continence after radical cystoprostatectomy and ileal orthotopic bladder substitution?
     Eur Urol. 2008;53:1040-6.
     PubMed     Text format     Related articles    Abstract available
     
     
     
227. RABER M , Scattoni V, Roscigno M, Deho F, et al
     Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial.
     Eur Urol. 2008;53:967-73.
     PubMed     Text format     Related articles    Abstract available
     
     
     
228. VON KNOBLOCH R
     Editorial comment on: topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial.
     Eur Urol. 2008;53:974-5.
     PubMed     Text format     Related articles   
     
     
     
229. SELLI C , Giannarini G
     Editorial comment on: topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial.
     Eur Urol. 2008;53:973-4.
     PubMed     Text format     Related articles   
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: